US/UK/Canada

Share

Pick a time period -
Tags ( Active)

SmartCella granted new European patent for the Extroducer delivery platform

SmartCella Holding AB (“SmartCella”) today announces that the European Patent Office (EPO) has granted a new European patent for the Extroducer® endovascular delivery platform.SmartCella is a global innovative biotechnology company that combines novel delivery platforms, such as the Extroducer, with cutting-edge cell and mRNA therapies. The Extroducer is a first-in-class endovascular delivery device that enables direct-to-tissue drug delivery. It addresses a significant unmet clinical need for a wide range of indications, enabling targeted delivery of various modalities to solid tumors and

XyloCor and SmartCella enter into license agreement for use of the Extroducer to administer novel gene therapy XC001 to the heart

· The Extroducer® Infusion Catheter System ® enables local delivery of XC001 to the heart without the need for surgery. · XC001 has achieved positive Phase 1/2 results in the EXACT Trial validating its transformative potential for treatment of refractory angina in patients who have exhausted available treatment options and have a debilitating quality-of-life.Wayne, PA, and Tullinge, Sweden July 10, 2024 —XyloCor Therapeutics, Inc. (“XyloCor”), a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, and SmartWise, a unit of SmartCella Holding

SmartCella raises EUR 50 million to accelerate growth and commercialization

SmartCella Holding AB (“SmartCella”) today announces a new share issue raising approximately EUR 50 million to accelerate growth and support commercialization of the Extroducer and the company’s cell and mRNA operations. The share issue was supported by existing large institutional investors such as Fjärde AP-fonden, AMF Pension and SEB-Stiftelsen, as well as a new long-term strategic investor, AstraZeneca (committing to approximately half of the share issue) and the new larger institutional investors Handelsbanken Fonder and RoosGruppen AB, at a pre-money valuation of approximately EUR 500

Senior life science and medical specialists join SmartCella’s Board of Directors

SmartCella Holding AB (“SmartCella”) held its 2024 Annual General Meeting on June 10. The company welcomed investors to its state-of-the art clinical GMP manufacturing facility in Stockholm to learn more about the progress of SmartCella during the last 12 months. In addition, the investors met and interacted with the new board members who all hold unique life science industry and medical expertise. The newly appointed Board of Directors will play a pivotal role as SmartCella embarks on its next strategic development phase.SmartCella is an innovative biotechnology company with a vision to

SmartCella strengthens team with Dr Ricardo Baptista as CTO

SmartCella Holding AB today announces that Dr Ricardo Baptista has been appointed Chief Technology Officer (CTO) and Head of Procella. Ricardo is an experienced Biochemical Engineer with almost 20-years of global experience in the medical biotechnology industry. He has a significant track record of leading technical teams at key cell and gene therapy companies, globally. Ricardo will be a member of SmartCella’s Executive Management Team and be based in Stockholm head office.SmartCella is an innovative biotechnology company developing stem cell and RNA-based therapies in combination with

SmartCella AB appoints Oskar Steneryd as new CFO

SmartCella Holding AB today announces that Oskar Steneryd has been appointed new Chief Financial Officer (CFO). Oskar Steneryd assumes the role on April 1, 2024, and most recently was Investment Director at Impilo, a Nordic-based investment company focused on the healthcare sector. Oskar will be a member of SmartCella’s Executive Management Team, based in the Stockholm head office.SmartCella is an innovative biotechnology company developing stem cell and RNA-based therapies in combination with novel delivery devices such as the FDA-cleared Extroducer. Oskar Steneryd’s recruitment adds

SmartCella obtains approval for GMP manufacturing and quality control testing of cell therapies

SmartCella, through its business unit ProCella, has been approved by the Swedish Medicinal Product Agency for manufacturing and quality control testing of sterile biological medicinal products for cell therapy.SmartCella is pleased to announce that ProCella has been granted manufacturing authorization as well as Good Manufacturing Practice (GMP) certification from the Swedish Medicinal Product Agency. The approvals signify the ability to start clinical production of cell-based therapies for clinical studies. The facility, located at SmartCella’s headquarters in Tullinge near Karolinska

SmartCella strengthens team by recruiting Dr. Nina Bauer as Chief Business Officer

SmartCella Holding AB today announces that Dr. Nina Bauer, MBA, has been appointed Chief Business Officer and Head of Smartwise. Nina Bauer joins in January 2024 from MilliporeSigma, where she most recently held the role of Global Head of Commercial, Viral Vector and Biologics CDMO. She will be a member of the SmartCella Exceutive Management Team, and based in Boston (MA, USA).SmartCella is an innovative biotech and medtech company that combines the development of future stem cell and RNA-based therapies and methods for administering such treatments via targeted delivery into organs and

Niklas Prager appointed new CEO of SmartCella

SmartCella Holding AB today announces that Niklas Prager has been appointed as the new CEO. SmartCella is an innovative biotech and medtech company that combines targeted delivery of medical substances to organs and tumors through a unique device, and the development of future stemcell and RNA-based treatments and methods for administering such treatments.Niklas Prager has extensive and solid experience from the global pharma industry and has held leadership positions in research-focused pharmaceutical companies such as Merck/MSD and Pfizer, with both Sweden and the USA as a base. He has

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media